Page 4 - Derek Jantz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: Precision BioSciences (NASDAQ: DTIL) shares are trading higher after the company reported its ARCUS platform showed a promising gene editing approach for transthyretin amyloidosis. "We're excited about the growing body of data demonstrating this ‘one and done' approach with ARCUS, and what it may mean for transforming the treatment of rare genetic diseases in humans," said Derek Jantz, Chief Scientific Officer and co-founder of Precision BioSciences. Precision BioSciences is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverage...

Search jobs Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder will participate in a fireside chat at the Truist Securities 2021 Life Sciences Virtual Series. Details for the fireside chat are below: The Truist Securities 2021...

Share: DURHAM, N.C., April 06, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences Inc. (NASDAQ:DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced a Chief Executive Officer transition plan and the initiation of a public search for a new CEO. Matt Kane, Co-Founder and Chief Executive Officer, is expected to continue in his current leadership capacity and as a board member until his successor has been identified. Mr. Kane will also serve as an advisor for a period of time after ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety ... Precision BiosciencesFebruary 19, 2021 GMT DURHAM, N.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company, today announced the publication of a paper in Molecular Therapy describing three-year follow-up data showing long-term stable reduction of low-density lipoprotein (LDL) cholesterol levels in nonhuman primates (NHPs) following in v...

Feb 19, 2021 10:05am Precision BioSciences' treatment could offer an alternative to fighting heart disease with PCSK9-lowering drugs like Amgen’s Repatha as well as Sanofi and Regeneron’s Praluent, researchers said. (Pixabay) Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the approach—designed as a one-time treatment—holds promise for treating familial hypercholesterolemia, high cholesterol that’s caused by abnormalities in the ge...